Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALM1 | P0DP23 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
| ▸ | KAT7 | O95251 | 1/20 | 0.34 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.34 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29084377 | 0.82 | KCNH2 (0.50) | ALDH1A1SMN1; SMN2TDP1TAAR1HPGD | |
| SCHEMBL29348977 | 0.80 | ESR1 (0.48) | TAAR1 | |
| SCHEMBL12848465 | 0.78 | TAAR1 (0.41) | ALDH1A1SMN1; SMN2TDP1TAAR1HTR2B | |
| SCHEMBL16598215 | 0.76 | L3MBTL1 (0.44) | ALDH1A1SMN1; SMN2L3MBTL1TDP1TAAR1 | |
| SCHEMBL12794242 | 0.76 | KAT7 (0.39) | ALDH1A1SMN1; SMN2TDP1HPGDTSHR | |
| SCHEMBL17239520 | 0.71 | PDE10A (0.46) | ALDH1A1L3MBTL1HPGDTSHRSCN9A | |
| SCHEMBL27072915 | 0.70 | CALM1 (0.55) | CALM1ALDH1A1RAB9ASMN1; SMN2L3MBTL1 | |
| Hydrochloric Acid SCHEMBL4829192 | 0.69 | HIF1A (0.39) | ALDH1A1TSHR | |
| SCHEMBL64435 | 0.67 | L3MBTL1 (0.68) | CALM1ALDH1A1RAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL415622 | 0.67 | CALM1 (0.50) | CALM1ALDH1A1RAB9ASMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4142732-B1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-12016312-B2 | Animal models, screening methods, and treatment methods for intraocular diseases or disorders | Smilebiotek Zhuhai Limited (CN) | 2024-06-25 | — | — | US | disclosed |
| CN-110267960-A | Substituted pyrazolo [1,5-a] pyrazine compound as RET kinase inhibitor | 阿雷生物药品公司 | 2019-09-20 | — | — | CN | disclosed |
| CN-105658642-B | Fibroblast growth factor receptor inhibitors | 蓝图药品公司 | 2019-05-03 | — | — | CN | disclosed |
| CN-103826661-B | Novel binding agent-drug conjugates (ADCs) and uses thereof | 西雅图基因公司 | 2019-03-05 | — | — | CN | disclosed |
| CN-108193309-A | Ultra-fine denier polyester filament yarn and preparation method thereof | 海盐县硕创服装研究所 | 2018-06-22 | — | — | CN | disclosed |
| CN-107849010-A | 3, 3-difluoropiperidine carbamate heterocycles as NR2B NMDA receptor antagonists | 卢郡控股(开曼)有限公司 | 2018-03-27 | — | — | CN | disclosed |
| US-8153673-B2 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2012-04-10 | — | — | US | disclosed |
| US-20110003853-A1 | Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2011-01-06 | — | — | US | disclosed |
| US-20100273849-A1 | Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2010-10-28 | — | — | US | disclosed |
| US-20080262045-A1 | Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2008-10-23 | — | — | US | disclosed |
| US-7427631-B2 | especially as inhibitors of MMP12 | ASTRAZENECA AB (SE) | 2008-09-23 | — | — | US | disclosed |
| US-20080171882-A1 | Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | US | disclosed |
| US-7368465-B2 | Respiratory system disorders; antiarthritic agents; anticancer agents; bone disorders | ASTRAZENECA AB (SE) | 2008-05-06 | — | — | US | disclosed |
| US-20040138276-A1 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2004-07-15 | — | — | US | disclosed |
| US-5968725-A | MATERIAL COMPRISING ON SUPPORT SILVER HALIDE PHOTOSENSITIVE LAYER CONTAINING ORGANIC SILVER SALT, REDUCING AGENT, ULTRAHIGH CONTRAST PROMOTING AGENT, SELECTED HETEROCYCLIC MERCAPTO COMPOUND | FUJI PHOTO FILM CO., LTD. (JP) | 1999-10-19 | — | — | US | disclosed |
| EP-0385999-A1 | APPLICATION OF 4- 1-OXOALKYL]-2,5-OXAZOLIDINEDIONES IN SELECTIVE STEREOSPECIFIC FORMATION OF BIOLOGICALLY ACTIVE BETA-LACTAMS. | UNIV CINCINNATI (US) | 1990-09-12 | — | — | EP | disclosed |
| WO-1988010256-A1 | APPLICATION OF 4-[1-OXOALKYL]-2,5-OXAZOLIDINEDIONES IN SELECTIVE STEREOSPECIFIC FORMATION OF BIOLOGICALLY ACTIVE BETA-LACTAMS | UNIVERSITY OF CINCINNATI (US) | 1988-12-29 | — | — | WO | disclosed |
| US-4769316-A | Method for restraining the formation of re-reversal negative image in direct positive silver halide photographic materials | FUJI PHOTO FILM CO., LTD. (JP) | 1988-09-06 | — | — | US | disclosed |
| US-4607006-A | Silver halide photographic light-sensitive material containing non-spectral sensitizing electron donative silver halide adsorptive compound | FUJI PHOTO FILM CO., LTD. (JP) | 1986-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003853-A1 | Metalloproteinase Inhibitors | MMP9, MMP12, MMP14 | CALM1 2925/4885ALDH1A1 612/4885RAB9A 2412/4885 |
| US-20100273849-A1 | Metalloproteinase Inhibitors | MMP9, MMP12, MMP11 | CALM1 2829/4885ALDH1A1 1381/4885RAB9A 1625/4885 |
| US-20080171882-A1 | Metalloproteinase Inhibitors | MMP9, MMP12, MMP14 | CALM1 2925/4885ALDH1A1 612/4885RAB9A 2412/4885 |
| US-20080262045-A1 | Metalloproteinase Inhibitors | MMP9, MMP12, MMP11 | CALM1 2829/4885ALDH1A1 1381/4885RAB9A 1625/4885 |
| US-12016312-B2 | Animal models, screening methods, and treatment methods for intraocular diseases or disorders | MB, MYOC, PDE6A | CALM1 3826/4885ALDH1A1 1091/4885RAB9A 1921/4885 |
| US-20040138276-A1 | Metalloproteinase inhibitors | MMP9, MMP11, MMP7 | CALM1 2737/4885ALDH1A1 1172/4885RAB9A 1251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.